|Bid||9.34 x 1300|
|Ask||9.35 x 2900|
|Day's Range||9.07 - 9.50|
|52 Week Range||4.78 - 10.32|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 8, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.30|
Catalyst Pharma (CPRX) gains on the successful launch of Firdapse. The company is looking to develop drug for additional indications.
Recro Pharma (REPH) delivered earnings and revenue surprises of 87.34% and 22.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 10 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
MALVERN, Philadelphia, May 10, 2019 -- Recro Pharma, Inc. (NASDAQ:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing.
Midwood Capital Management explained recent Recro Pharma (NASDAQ:REPH) stock price fluctuations in its Q1 2019 Investor Letter. If you are interested you can find a copy of the letter here. The fund also disclosed the quarterly return of 10.6%, and an annualized return since inception of 9.5%. "Recro Pharma, Inc. (REPH; $8.36; $184million market cap): […]
Recro Pharma, Inc. (REPH) today announced that it will report first quarter financial results on Friday, May 10, 2019. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Friday, May 10, 2019 to discuss the financial results and recent operational highlights. To access the conference call, please dial (844) 243-4691 (local) or (225) 283-0379 (international) at least 10 minutes prior to the start time and refer to conference ID 8294704.
Recro Pharma (REPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Artko Capital recently released its Q1 2019 Investor Letter, which you can track down here. In it, the fund reported its quarterly return of 10.3% and also shared its views on some companies in its portfolio. Among the stocks discussed was Recro Pharma, Inc. (NASDAQ:REPH), for which the fund wrote the following: Recro Pharma (REPH)-We […]
Recro Pharma, Inc. (REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that Recro Gainesville LLC, its CDMO division, has amended its existing license and supply agreement with Teva Pharmaceutical to extend the agreement for six years, effective January 1, 2019.
Recro Pharma, Inc. (REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) segment, today announced a moderated poster presentation highlighting new intravenous (IV) meloxicam data at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting, hosted by the American Society of Regional Anesthesia and Pain Medicine, taking place April 11-13, 2019, in Las Vegas. In this study, the researchers conducted a network meta-analysis (NMA) assessing the safety and efficacy of IV meloxicam relative to other IV non-opioid analgesics for moderate to severe pain. The analysis was conducted by comparing Recro Pharma’s IV meloxicam data to 17 randomized controlled clinical trials evaluating several non-opioid analgesics, including acetaminophen, ketorolac, placebo combined with a non-opioid and placebo combined with an opioid, across three procedure categories: abdominal, bunionectomy and orthopedic.
Recro Pharma Inc. is eliminating about 50 positions in its acute care segment, and seeking a partner to commercialize its lead new drug candidate. Both moves come about two weeks after the Food and Drug Administration for a second time turned down the Malvern, Pa, pharmaceutical company's new drug application for intravenous meloxicam. Recro is seeking to market IV meloxicam, a non-opioid, as a treatment to manage moderate-to-severe pain.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 3) Denali Therapeutics Inc (NASDAQ: DNLI ) GALAPAGOS NV/S ...
Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company with a high-performing contract development and manufacturing (CDMO) Segment, today announced an initiative that will reduce the operating expenses of its Acute Care Segment, including a reduction in staff of approximately 50 employees. Some Acute Care Segment employees engaged in efforts to select a partner for and in obtaining FDA approval of (IV) meloxicam were retained. This initiative is expected to significantly lower operating expenses following receipt of a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) Office of Drug Evaluation II regarding its New Drug Application (NDA).
FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.
The company has vowed to continue to work with the FDA to get approval for its non-opioid pain medicine.
Recro, a micro-cap specialty pharma company that focuses on therapeutics for hospitals and other acute care settings, announced Friday the FDA handed down a complete response letter for its NDA seeking approval for intravenous meloxicam for the management of moderate to severe pain. The investigational drug was issued a complete response letter for the first time in May 2018, with the FDA reasoning that data from ad hoc analyses and selective secondary endpoints suggested that the analgesic effect of the asset doesn't meet its expectations.
Shares of Recro Pharma Inc. plummeted 46% to pace all premarket decliners Monday, after the specialty pharmaceutical company said it received a second "complete response letter" (CRL) from the Food and Drug Administration regarding the new drug application for intravenous meloxicam for the treatment of moderate to severe pain. The comments in the CRL, which was unveiled late Friday, focused on onset and duration, saying the delayed onset failed to meet prescriber expectations for intravenous drugs, and citing regulatory concerns over the role of meloxicam as a monotherapy in acute pain. The company said it "strongly disagrees" with the FDA. "We are extremely disappointed with the receipt of a second CRL from the FDA," said Chief Executive Gerri Henwood. "We remain steadfast in our belief that IV meloxicam holds significant potential as a treatment option for moderate to severe pain in multiple clinical settings and remain committed to pursuing a path to regulatory approval." The stock had run up 44% over the past three months through Friday, while the S&P 500 had gained 19%.
Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the appointment of Arnaud Ajdler to the Company’s Board of Directors. Mr. Ajdler, managing partner of Engine Capital, L.P., brings over 15 years of finance and corporate governance experience to Recro’s Board. “Arnaud brings to Recro significant investment and corporate governance experience gained from his participation on multiple public company boards,” said Gerri Henwood, President and Chief Executive Officer of Recro Pharma.